3,4-Dihydropyrazino[2,3-b]pyrazin-2(1H)-one compounds as MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway

Provided herein is a method for preparing a compound of formula (II):wherein the method comprising contacting a compound of formula (VI):with R1-Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1, R2, R3and Y are as defined h...

Full description

Saved in:
Bibliographic Details
Main Authors Sankar, Sabita, Riggs, Jennifer, Papa, Patrick, Parnes, Jason, Shevlin, Graziella I, Perrin-Ninkovic, Sophie, Harris, Roy, Elsner, Jan, Tehrani, Lida, SAPIENZA, John, Xu, Weiming, Zhao, Jingjing, Fultz, Kimberly Elizabeth, Narla, Rama K, Mortensen, Deborah, Madakamutil, Loui, Lee, Branden, Packard, Garrick K
Format Patent
LanguageEnglish
Hungarian
Published 28.07.2016
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein is a method for preparing a compound of formula (II):wherein the method comprising contacting a compound of formula (VI):with R1-Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1, R2, R3and Y are as defined herein.
Bibliography:Application Number: HUE14158171